checkAd
    Startseite > Aktien > Innate Pharma > Nachrichten
    Innate Pharma Aktie
    2,6400
     
    EUR
    -1,12 %
    -0,0300 EUR
    Letzter Kurs 27.05.24 Tradegate
    2,6200
     
    EUR
    1.146 STK
    Geldkurs 15:51:23
    2,6450
     
    EUR
    1.135 STK
    Briefkurs 15:51:23
    ISIN: FR0010331421 · WKN: A0LCUJ · SYM: IDD · Frankreich

    Neueste Nachrichten

    Innate Pharma Announces Its Participation in Upcoming Investor Conferences
    07:00 Uhr · Business Wire (engl.) · Innate Pharma
    Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
    24.05.24 · Business Wire (engl.) · Innate Pharma
    Outcome of Innate Pharma’s 2024 Annual General Meeting
    23.05.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma: Clarification Regarding SAR443579 Designation
    21.05.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
    15.05.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
    14.05.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
    07.05.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
    15.04.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
    15.04.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
    10.04.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Announces Its Participation in Upcoming Investor Conference
    09.04.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
    05.04.24 · Business Wire (engl.) · Innate Pharma